Opportunities for treating opportunistic vaginal infections during pregnancy


Cite item

Full Text

Abstract

The aim of the study was to evaluate the effectiveness of treatment of women with opportunistic vaginal infections during pregnancy. Materials and methods. A prospective cohort study included 330 pregnant women, of whom 151 were diagnosed with bacterial vaginosis (BV), 37 had aerobic vaginitis (AB), 109 had vulvovaginal candidiasis (VC), 20 had a combination of VC + BV. When carrying out antibiotic therapy in the early stages of pregnancy, the principle of local treatment was observed. Results. Most often (46.0%), vaginal infections were detected when women were treated early in pregnancy. In the treatment of BV in the early stages of pregnancy with antiseptic chlorhexidine, a positive result of therapy was noted in 97.6% of women. Therapy with metronidazole or clindamycin BV in women who applied in the II and III trimesters, gave a positive result, respectively, in 90.0% and 89.5% of cases. The course of therapy with chlorhexidine pregnant women with AB was effective in 91.7% of cases with treatment in the first trimester and 92.0% in treatment in the II and III trimesters. In the treatment of VC in early pregnancy, natamycin was effective in 95.0% of women. In the II and III trimesters, econazole treatment was successful in 88.2% and 88.6%, respectively. In the treatment of combination of BV + VC in early gestation, the complex course of chlorhexidine + natamycin was effective in 76.5% of women, in II and III trimesters Neo-Penotran Forte was effective in 93.8% of pregnant women. Relapses of vaginal infections were observed in 34 pregnant women (10.3%). Superinfection with fungi was noted in 9.3% of cases of BV treatment and in 8.1% of pregnant women with AB. Among women observed from early pregnancy, there were no cases of premature birth, manifestations of intrauterine infections were noted in 5.3% of newborns. At treatment in the II and III trimesters, premature birth was in 6.5% and 13.5% of women, and manifestations of intrauterine infections - in 15.3% of newborns. Thus, microbiological monitoring of timely detection and treatment of opportunistic vaginal infections in pregnant at-risk groups showed the advisability of treating these infections in early gestation.

About the authors

T E Karapetyan

V.I.Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation

Email: tomamed02@mail.ru
д-р мед. наук, ст. науч. сотр. акушерского отд-ния 117997, Russian Federation, Moscow, ul. Akademika Oparina, d. 4

V V Muravieva

V.I.Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation

Email: v_muraviеva@oparina4.ru
канд. биол. наук, ст. науч. сотр. отд. микробиологии 117997, Russian Federation, Moscow, ul. Akademika Oparina, d. 4

A S Ankirskaya

V.I.Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation

Email: a_ankirskaya@oparina4.ru
д-р мед. наук, проф., науч. консультант отд. микробиологии 117997, Russian Federation, Moscow, ul. Akademika Oparina, d. 4

L A Lyubasovskaya

V.I.Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation

Email: labmik@yandex.ru
канд. мед. наук, зав. отд-нием клин. фармакологии отд. микробиологии и клин. фармакологии 117997, Russian Federation, Moscow, ul. Akademika Oparina, d. 4

T V Priputnevich

V.I.Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation

Email: priput1@gmail.com
д-р мед. наук, зав. отд. микробиологии и клин. фармакологии 117997, Russian Federation, Moscow, ul. Akademika Oparina, d. 4

References

  1. Анкирская А.С., Муравьева В.В. Интегральная оценка состояния микробиоты влагалища. Диагностика оппортунистических вагинитов (Медицинская технология). М., 2011.
  2. Васильченко О.Н., Баев О.Р. Эффективность лечения бактериального вагиноза у беременных антисептиком октенидина дигидрохлорид. Мед. совет. 2016; 12: 21-23.
  3. Подгорная А.В., Махмутходжаев А.Ш., Михеенко Г.А., Кох Л.И. Ведение беременных женщин с рецидивирующим бактериальным вагинозом. Соврем. проблемы науки и образования. 2016 (6): 172.
  4. Уиткин Стивен С. Вагинальный микробиом, механизмы антимикробной защиты влагалища и клиническая проблема снижения риска преждевременных родов, связанных с инфицированием. Акушерство и гинекология: новости, мнения, обучение. 2016; 1 (11): 20-6
  5. Aguin T, Akins R.A, Sobel J.D. High-dose vaginal maintenance metronidazole for recurrent bacterial vaginosis: a pilot study. Sex Transm Dis 2014; 41 (5): 290-1.
  6. Amaya-Guio J, Viveros-Carreño D.A, Sierra-Barrios E.M. et al. Antibiotic treatment for the sexual partners of women with bacterial vaginosis. Cochrane Database Syst Rev 2016; 10: CD011701.
  7. Beghini J, Giraldo P.C, Linhares I.M. et al. Neutrophil Gelatinase-Associated Lipocalin Concentration in Vaginal Fluid: Relation to Bacterial Vaginosis and Vulvovaginal Candidiasis. Reprod Sci 2015; 22 (8): 964-8.
  8. Catallozzi M, Fraiz L, Hargreaves K.M. et al. Pregnant women's attitudes about topical microbicides for the prevention and treatment of bacterial vaginosis during pregnancy. Int J STD AIDS 2016.
  9. Chavoustie S.E, Jacobs M, Reisman H.A. et al. Metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosis: a dose-ranging study. J Low Genit Tract Dis 2015; 19 (2): 129-34.
  10. Foxman B, Wen A, Srinivasan U. et al. Mycoplasma, bacterial vaginosis-associated bacteria BVAB3, race, and risk of preterm birth in a high-risk cohort. Am J Obstet Gynecol 2014; 210 (3): 226.
  11. Haahr T, Ersbøll A.S, Karlsen M.A. et al. Treatment of bacterial vaginosis in pregnancy in order to reduce the risk of spontaneous preterm delivery - a clinical recommendation. Acta Obstet Gynecol Scand 2016; 95 (8): 850-60.
  12. Heczko P.B, Tomusiak A, Adamski P et al. Supplementation of standard antibiotic therapy with oral probiotics for bacterial vaginosis and aerobic vaginitis: a randomised, double-blind, placebo-controlled trial. BMC Womens Health 2015; 15: 115.
  13. Hilbert D.W, Smith W.L, Chadwick S.G.et al. Development and Validation of a Highly Accurate Quantitative Real-Time PCR Assay for Diagnosis of Bacterial Vaginosis. J Clin Microbiol 2016; 54 (4): 1017-24.
  14. Liang Q, Li N, Song S. et al. High-dose nifuratel for simple and mixed aerobic vaginitis: A single-center prospective open-label cohort stud. J Obstet Gynaecol Res 2016; 42 (10): 1354-60.
  15. Liu M.B, Xu S.R, He Y. et al. Diverse vaginal microbiomes in reproductive-age women with vulvovaginal candidiasis. PLoS One 2013; 8(11).
  16. Mengistie Z, Woldeamanuel Y, Asrat D, Yigeremu M. Comparison of clinical and gram stain diagnosis methods of bacterial vaginosis among pregnant women in Ethiopia. J Clin Diagn Res 2013; 7 (12): 2701-3.
  17. Nasioudis D, Linhares I.M, Ledger W.J, Witkin S.S. Bacterial vaginosis: a critical analysis of current knowledge. BJOG 2017; 124 (1): 61-9.
  18. Nelson D.B, Komaroff E, Nachamkin I et al. Relationship of selected bacterial vaginosis-associated bacteria to Nugent score bacterial vaginosis among urban women early in pregnancy. Sex Transm Dis 2013; 40 (9): 721-3.
  19. Nelson D.B, Hanlon A.L, Wu G. et al. First Trimester Levels of BV-Associated Bacteria and Risk of Miscarriage Among Women Early in Pregnancy. Matern Child Health J 2015; 19 (12): 2682-7.
  20. Singh R.H, Zenilman J.M, Brown K.M. et al. The role of physical examination in diagnosing common causes of vaginitis: a prospective study. Sex Transm Infect 2013; 89 (3): 185-90.
  21. Sioutas A, Sandström A, Fiala C. et al. Effect of bacterial vaginosis on the pharmacokinetics of misoprostol in early pregnancy. Hum Reprod 2012; 27 (2): 388-93.
  22. Subramaniam A, Kumar R, Cliver S.P. et al. Vaginal Microbiota in Pregnancy: Evaluation Based on Vaginal Flora, Birth Outcome, and Race. Am J Perinatol 2016; 33 (4): 401-8.
  23. Sungkar A, Purwosunu Y, Aziz M.F. et al. Influence of early self-diagnosis and treatment of bacterial vaginosis on preterm birth rate. Int J Gynaecol Obstet 2012; 117 (3): 264-7.
  24. Sobel R, Sobel J.D. Metronidazole for the treatment of vaginal infections. Expert Opin Pharmacother 2015; 16 (7): 1109-15.
  25. Tellapragada C, Eshwara V.K, Bhat P. et al. Screening of vulvovaginal infections during pregnancy in resource constrained settings: Implications on preterm delivery. J Infect Public Health 2016; 16: 1876.
  26. Vieira-Baptista P, Lima-Silva J, Pinto C. et al. Bacterial vaginosis, aerobic vaginitis, vaginal inflammation and major Pap smear abnormalities. Eur J Clin Microbiol Infect Dis 2016; 35 (4): 657-64.
  27. Vitali B, Cruciani F, Picone.G et al. Vaginal microbiome and metabolome highlight specific signatures of bacterial vaginosis. Eur J Clin Microbiol Infect Dis 2015; 34 (12): 2367-76.
  28. Wang Z.L, Fu L.Y, Xiong Z.A. et al. Diagnosis and microecological characteristics of aerobic vaginitis in outpatients based on preformed enzymes. Taiwan J Obstet Gynecol 2016; 55 (1): 40-4.
  29. Xiao B, Niu X, Han N. et al. Predictive value of the composition of the vaginal microbiota in bacterial vaginosis, a dynamic study to identify recurrence-related flora. Sci Rep 2016; 6: 26674.
  30. Yang S, Reid G, Challis J.R. et al. Is there a role for probiotics in the prevention of preterm birth? Front Immunol 2015; 6: 62.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).